Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Venclexta

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Roche’s Genentech and Blueprint receive full FDA approval for Gavreto in lung cancer

The targeted therapy was granted accelerated approval for the NSCLC indication in 2020

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial

The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links